EP1404702A4 - Human secreted proteins - Google Patents

Human secreted proteins

Info

Publication number
EP1404702A4
EP1404702A4 EP02759068A EP02759068A EP1404702A4 EP 1404702 A4 EP1404702 A4 EP 1404702A4 EP 02759068 A EP02759068 A EP 02759068A EP 02759068 A EP02759068 A EP 02759068A EP 1404702 A4 EP1404702 A4 EP 1404702A4
Authority
EP
European Patent Office
Prior art keywords
secreted proteins
human secreted
human
proteins
secreted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02759068A
Other languages
German (de)
French (fr)
Other versions
EP1404702A2 (en
Inventor
Craig A Rosen
Steven M Ruben
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of EP1404702A2 publication Critical patent/EP1404702A2/en
Publication of EP1404702A4 publication Critical patent/EP1404702A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP02759068A 2001-03-21 2002-03-19 Human secreted proteins Withdrawn EP1404702A4 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US27734001P 2001-03-21 2001-03-21
US277340P 2001-03-21
US30617101P 2001-07-19 2001-07-19
US306171P 2001-07-19
US33128701P 2001-11-13 2001-11-13
US331287P 2001-11-13
PCT/US2002/009785 WO2002095010A2 (en) 2001-03-21 2002-03-19 Human secreted proteins

Publications (2)

Publication Number Publication Date
EP1404702A2 EP1404702A2 (en) 2004-04-07
EP1404702A4 true EP1404702A4 (en) 2009-07-08

Family

ID=27402891

Family Applications (7)

Application Number Title Priority Date Filing Date
EP02759068A Withdrawn EP1404702A4 (en) 2001-03-21 2002-03-19 Human secreted proteins
EP02782476A Withdrawn EP1414845A4 (en) 2001-03-21 2002-03-19 Human secreted proteins
EP02749512A Withdrawn EP1381622A2 (en) 2001-03-21 2002-03-19 Human secreted proteins
EP02723499A Withdrawn EP1379264A4 (en) 2001-03-21 2002-03-19 Human secreted proteins
EP02799146A Withdrawn EP1390390A4 (en) 2001-03-21 2002-03-19 Human secreted proteins
EP02780789A Withdrawn EP1423134A2 (en) 2001-03-21 2002-03-19 Human secreted proteins
EP02760994A Withdrawn EP1379132A4 (en) 2001-03-21 2002-03-19 Human secreted proteins

Family Applications After (6)

Application Number Title Priority Date Filing Date
EP02782476A Withdrawn EP1414845A4 (en) 2001-03-21 2002-03-19 Human secreted proteins
EP02749512A Withdrawn EP1381622A2 (en) 2001-03-21 2002-03-19 Human secreted proteins
EP02723499A Withdrawn EP1379264A4 (en) 2001-03-21 2002-03-19 Human secreted proteins
EP02799146A Withdrawn EP1390390A4 (en) 2001-03-21 2002-03-19 Human secreted proteins
EP02780789A Withdrawn EP1423134A2 (en) 2001-03-21 2002-03-19 Human secreted proteins
EP02760994A Withdrawn EP1379132A4 (en) 2001-03-21 2002-03-19 Human secreted proteins

Country Status (4)

Country Link
EP (7) EP1404702A4 (en)
AU (6) AU2002363296A1 (en)
CA (7) CA2441397A1 (en)
WO (7) WO2002095010A2 (en)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196164B2 (en) 1997-07-08 2007-03-27 Human Genome Sciences, Inc. Secreted protein HHTLF25
CA2295474A1 (en) 1997-07-08 1999-01-21 Human Genome Sciences, Inc. 123 human secreted proteins
EP1086223B1 (en) 1998-06-01 2009-07-29 Agensys, Inc. Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US20030149531A1 (en) 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US20060052321A1 (en) 2002-04-05 2006-03-09 Raitano Arthur B Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
US20040141975A1 (en) 1998-06-01 2004-07-22 Raitano Arthur B. Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
CN1387538A (en) 1999-01-15 2002-12-25 比奥根公司 Antagonists of TWEAK and of TWEAK receptor and their use to treat immunological disorders
EP1666490A3 (en) * 2000-07-25 2006-11-02 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7291719B2 (en) 2000-07-25 2007-11-06 Genentech, Inc. PRO4332 antibodies
WO2002048370A2 (en) 2000-10-31 2002-06-20 Diadexus, Inc. Compositions and methods relating to colon specific genes and proteins
US20020111302A1 (en) * 2000-11-30 2002-08-15 Y. Tom Tang Novel nucleic acids and polypeptides
EP1573024A4 (en) * 2001-04-10 2007-08-29 Agensys Inc Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
US20030119112A1 (en) 2001-06-20 2003-06-26 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
ES2537074T3 (en) 2001-09-06 2015-06-02 Agensys, Inc. Nucleic acid and corresponding protein called STEAP-1 useful in the treatment and detection of cancer
WO2003033727A1 (en) 2001-10-12 2003-04-24 Yamanouchi Pharmaceutical Co., Ltd. Method of screening cell death inhibitor
WO2003086311A2 (en) 2002-04-09 2003-10-23 Biogen, Inc. Methods for treating tweak-related conditions
AU2003900747A0 (en) * 2003-02-18 2003-03-06 Garvan Institute Of Medical Research Diagnosis and treatment of pancreatic cancer
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
WO2005019258A2 (en) * 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP2380985B1 (en) 2003-09-23 2014-01-01 University of North Carolina at Chapel Hill Cells expressing vitamin K epoxide reductase and use thereof
EP2189523B1 (en) * 2003-10-14 2012-01-04 Baxter International Inc. Vitamin K epoxide recycling polypeptide VKORC1, a therapeutic target of coumarin and their derivatives
US20070269421A1 (en) * 2004-02-03 2007-11-22 Bayer Healthcare Ag Diagnostics and Therapeutics for Diseases Associated with Plasma Glutamate Carboxypeptidase (Pgcp)
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
NZ550816A (en) 2004-04-22 2009-12-24 Agensys Inc Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
NZ553581A (en) * 2004-09-01 2011-04-29 Dynavax Tech Corp Methods and compositions for inhibition of innate immune responses and autoimmunity using immunoregulatory polynucleotides with a TGC sequence
EP1799850A4 (en) * 2004-09-07 2009-02-11 Telethon Inst For Child Health Method of diagnosing and/or predicting the development of an allergic disorder
CA2579349A1 (en) * 2004-09-07 2006-03-16 Telethon Institute For Child Health Research Agents for treatment or prevention of an allergic disorder
DK2529619T3 (en) 2005-02-17 2016-01-11 Biogen Ma Inc Treatment of neurological disorders
JP2008531026A (en) 2005-02-28 2008-08-14 バクスター・インターナショナル・インコーポレイテッド Recombinant co-expression of vitamin K epoxide reductase subunit 1 to improve vitamin K-dependent protein expression
US20090325226A1 (en) 2005-03-15 2009-12-31 Stafford Darrel W Methods and Compositions for Producing Active Vitamin K-Dependent Proteins
EP1885388B1 (en) 2005-05-10 2013-09-11 Biogen Idec MA Inc. Treating and evaluating inflammatory disorders
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
GB2445882B (en) * 2005-09-01 2011-02-23 Florey Howard Inst Prophylactic and therapeutic agents and compositions and uses therefor and methods for determining the presence or severity of neuronal damage
GB0521488D0 (en) * 2005-10-21 2005-11-30 Ares Trading Sa Integral membrane protein
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
EP2061814B1 (en) 2006-10-27 2012-06-06 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
CA2669424A1 (en) 2006-11-07 2008-05-29 Merck & Co., Inc. Antagonists of pcsk9
US8093222B2 (en) * 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
US8263353B2 (en) 2007-03-27 2012-09-11 Merck Sharp & Dohme Corp. Method for detecting autoprocessed, secreted PCSK9
JOP20080381B1 (en) 2007-08-23 2023-03-28 Amgen Inc Antigen Binding Proteins to Proprotein Convertase subtillisin Kexin type 9 (pcsk9)
EP2209896B1 (en) 2007-10-26 2017-03-01 Dynavax Technologies Corporation Methods and compositions for inhibition of immune responses and autoimmunity
EP3536336A1 (en) * 2007-11-30 2019-09-11 Siemens Healthcare Diagnostics Inc. Adiponectin receptor fragments and methods of use
AR070315A1 (en) 2008-02-07 2010-03-31 Merck & Co Inc ANTIBODIES 1B20 ANTAGONISTS OF PCSK9
AR070316A1 (en) 2008-02-07 2010-03-31 Merck & Co Inc PCSK9 ANTAGONISTS (SUBTILISINE-KEXINA TYPE 9 PROPROTEIN)
US8748115B2 (en) 2008-12-12 2014-06-10 Merck Sharp & Dohme Corp. PCSK9 immunoassay
WO2011053759A1 (en) 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Ax1 and ax189 pcsk9 antagonists and variants
WO2011053783A2 (en) 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Ax213 and ax132 pcsk9 antagonists and variants
SG186380A1 (en) 2010-06-16 2013-01-30 Dynavax Tech Corp Methods of treatment using tlr7 and/or tlr9 inhibitors
BR112013005872A2 (en) 2010-09-22 2019-09-24 Alios Biopharma Inc compounds, pharmaceutical composition and their uses
EP2655607A4 (en) 2010-12-21 2014-05-14 Univ North Carolina Methods and compositions for producing active vitamin k-dependent proteins
AU2012358804B2 (en) 2011-12-22 2018-04-19 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
US8916538B2 (en) 2012-03-21 2014-12-23 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
EP2827876A4 (en) 2012-03-22 2015-10-28 Alios Biopharma Inc Pharmaceutical combinations comprising a thionucleotide analog
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9051378B1 (en) 2014-07-15 2015-06-09 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US9682218B2 (en) 2013-12-23 2017-06-20 Carefusion 2200, Inc. Pleurodesis device and method
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
GB2572918B (en) 2016-12-23 2023-02-15 Harvard College Gene editing of PCSK9
SG11201909218RA (en) 2017-04-03 2019-11-28 Hoffmann La Roche Antibodies binding to steap-1
WO2018237212A1 (en) 2017-06-22 2018-12-27 The Procter & Gamble Company Films including a water-soluble layer and a vapor-deposited organic coating
US10450119B2 (en) 2017-06-22 2019-10-22 The Procter & Gamble Company Films including a water-soluble layer and a vapor-deposited inorganic coating

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000004140A1 (en) * 1998-07-15 2000-01-27 Human Genome Sciences, Inc. 71 human secreted proteins
WO2002026931A2 (en) * 2000-09-25 2002-04-04 Human Genome Sciences, Inc. 71 human secreted proteins

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100236393B1 (en) * 1996-02-02 1999-12-15 나까니시 히로유끼 A pharmaceutical preparation containing a human growth hormone
US5858716A (en) * 1997-05-30 1999-01-12 Smithkline Beecham Corporation H2CAA71 polynucleotides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000004140A1 (en) * 1998-07-15 2000-01-27 Human Genome Sciences, Inc. 71 human secreted proteins
WO2002026931A2 (en) * 2000-09-25 2002-04-04 Human Genome Sciences, Inc. 71 human secreted proteins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HSU SHEAU YU ET AL: "Characterization of two LGR genes homologous to gonadotropin and thyrotropin receptors with extracellular leucine-rich repeats and a G protein-coupled, seven-transmembrane region", MOLECULAR ENDOCRINOLOGY, vol. 12, no. 12, December 1998 (1998-12-01), pages 1830 - 1845, XP002528150, ISSN: 0888-8809 *
LOH E D ET AL: "Molecular Characterization of a Novel Glycoprotein Hormone G-Protein-Coupled Receptor", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 282, no. 3, 6 April 2001 (2001-04-06), pages 757 - 764, XP003002810, ISSN: 0006-291X *

Also Published As

Publication number Publication date
WO2002076488A1 (en) 2002-10-03
EP1381622A2 (en) 2004-01-21
WO2002095010A2 (en) 2002-11-28
EP1379132A2 (en) 2004-01-14
AU2002326293A1 (en) 2003-01-02
CA2441840A1 (en) 2002-11-28
EP1390390A4 (en) 2009-07-08
EP1379264A4 (en) 2009-07-08
EP1414845A4 (en) 2009-07-08
AU2002363296A1 (en) 2003-05-12
EP1390390A2 (en) 2004-02-25
WO2002102993A2 (en) 2002-12-27
EP1414845A2 (en) 2004-05-06
EP1423134A2 (en) 2004-06-02
CA2441702A1 (en) 2002-12-27
AU2002354719A1 (en) 2003-01-21
AU2002324424A1 (en) 2002-12-03
CA2441397A1 (en) 2002-10-03
EP1404702A2 (en) 2004-04-07
WO2002102994A3 (en) 2003-07-24
CA2441416A1 (en) 2003-01-16
WO2002090526A2 (en) 2002-11-14
WO2002095010A3 (en) 2004-02-12
WO2003038063A3 (en) 2003-12-11
EP1379264A1 (en) 2004-01-14
WO2002090526A3 (en) 2003-10-30
WO2002102993A3 (en) 2004-03-25
CA2441755A1 (en) 2003-05-08
AU2002332391A1 (en) 2003-01-02
WO2002102994A2 (en) 2002-12-27
WO2003038063A2 (en) 2003-05-08
WO2003004622A2 (en) 2003-01-16
CA2441832A1 (en) 2002-12-27
AU2002320013A1 (en) 2002-11-18
CA2441417A1 (en) 2002-11-14
WO2003004622A3 (en) 2004-02-19
EP1379132A4 (en) 2009-07-01

Similar Documents

Publication Publication Date Title
EP1379132A4 (en) Human secreted proteins
EP1385381A4 (en) Human secreted proteins
EP1251863A4 (en) 22 human secreted proteins
AU2002361452A8 (en) Secreted proteins
GB0218205D0 (en) Human ZZAP1 protein
IL162598A0 (en) Secreted protein
AU2002232596A1 (en) Secreted human proteins
AU2002354803A8 (en) Secreted proteins
EP1368468A4 (en) 83 human secreted proteins
AU2003301843A8 (en) 157 human secreted proteins
EP1385977A4 (en) Secreted proteins
AU2001294719A1 (en) Secreted human proteins
EP1370651A4 (en) 70 human secreted proteins
EP1417224A4 (en) Secreted proteins
AU2002365153A1 (en) 41 human secreted proteins
EP1404807A4 (en) 20 human secreted proteins
AU2002246998A1 (en) 50 human secreted proteins
AU2002348034A8 (en) 16 human secreted proteins
AU2002254275A1 (en) Human secreted proteins
AU2002303843A8 (en) Secreted proteins
AU2003211136A8 (en) 6 human secreted proteins
AU2002332483A1 (en) 13 human secreted proteins
AU2002247189A1 (en) 70 human secreted proteins
AU2002253985A1 (en) 83 human secreted proteins
EP1443818A4 (en) Novel secreted proteins and their uses

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20031021

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIC1 Information provided on ipc code assigned before grant

Ipc: C07H 21/02 20060101ALI20090527BHEP

Ipc: C07K 1/00 20060101AFI20040219BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20090605

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090915